Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price Target & Predictions
DCPH Stock Forecast
Deciphera Pharmaceuticals stock forecast is as follows: an average price target of $26.32 (represents a 2.85% upside from DCPH’s last price of $25.59) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
DCPH Price Target
The average price target for Deciphera Pharmaceuticals (DCPH) is $26.32 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $25.00. This represents a potential 2.85% upside from DCPH's last price of $25.59.
DCPH Analyst Ratings
According to 10 Wall Street analysts, Deciphera Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for DCPH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Deciphera Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 30, 2024 | Peter Lawson | Barclays | $26.00 | $25.27 | 2.89% | 1.60% |
| Apr 29, 2024 | Eun Yang | Jefferies | $25.60 | $25.30 | 1.21% | 0.04% |
| Apr 29, 2024 | Christopher Raymond | Raymond James | $25.00 | $25.29 | -1.15% | -2.31% |
| Apr 29, 2024 | Christopher Raymond | Raymond James | $25.60 | $25.25 | 1.41% | 0.04% |
| Feb 07, 2023 | - | Leerink Partners | $30.00 | $16.71 | 79.53% | 17.23% |
| Jan 04, 2023 | - | Leerink Partners | $28.00 | $15.94 | 75.66% | 9.42% |
| Jan 04, 2023 | - | Barclays | $9.00 | $15.94 | -43.54% | -64.83% |
| Sep 12, 2022 | - | H.C. Wainwright | $25.00 | $18.08 | 38.27% | -2.31% |
| Aug 05, 2022 | - | H.C. Wainwright | $20.00 | $16.58 | 20.63% | -21.84% |
The latest Deciphera Pharmaceuticals stock forecast, released on Apr 30, 2024 by Peter Lawson from Barclays, set a price target of $26.00, which represents a 2.89% increase from the stock price at the time of the forecast ($25.27), and a 1.60% increase from DCPH last price ($25.59).
Deciphera Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $25.55 |
| Last Closing Price | $25.59 | $25.59 | $25.59 |
| Upside/Downside | -100.00% | -100.00% | -0.16% |
In the current month, the average price target of Deciphera Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Deciphera Pharmaceuticals's last price of $25.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 29, 2024 | Barclays | Underweight | Equal-Weight | Upgrade |
| Apr 29, 2024 | JMP Securities | Market Outperform | Market Perform | Downgrade |
| Apr 29, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| Apr 29, 2024 | Jefferies | - | Hold | Downgrade |
| Apr 29, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Oct 30, 2023 | Piper Sandler | - | Overweight | Upgrade |
| Aug 10, 2023 | Raymond James | - | Buy | Upgrade |
| Feb 07, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jan 06, 2023 | JonesTrading | - | Hold | Upgrade |
| Jan 04, 2023 | William Blair | - | Outperform | Initialise |
Deciphera Pharmaceuticals's last stock rating was published by Barclays on Apr 29, 2024. The company Upgrade its DCPH rating from "Underweight" to "Equal-Weight".
Deciphera Pharmaceuticals Financial Forecast
Deciphera Pharmaceuticals Revenue Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $48.29M | - | - | $33.45M | $36.34M | - | - | $29.22M | $24.20M | $23.22M | $23.57M | $25.16M | $19.49M | $15.45M | $7.09M | $62.00K | - | - | $25.00M |
| Avg Forecast | $72.50M | $62.53M | $55.60M | $50.40M | $54.83M | $53.33M | $49.46M | $46.20M | $45.93M | $39.45M | $36.09M | $35.69M | $35.97M | $33.08M | $30.56M | $26.88M | $23.41M | $23.47M | $21.93M | $22.46M | $18.65M | $6.71M | $877.78K | $56.98K | $1.25M | $454.55K | $2.00M |
| High Forecast | $72.50M | $62.53M | $55.60M | $50.40M | $54.83M | $53.33M | $51.95M | $46.20M | $47.26M | $41.44M | $36.09M | $35.69M | $35.97M | $33.08M | $30.56M | $28.34M | $24.68M | $24.75M | $23.12M | $23.68M | $19.66M | $7.07M | $925.56K | $68.38K | $1.32M | $479.29K | $2.11M |
| Low Forecast | $72.50M | $62.53M | $55.60M | $50.40M | $54.83M | $53.33M | $45.19M | $46.20M | $42.94M | $37.59M | $36.09M | $35.69M | $35.97M | $33.08M | $30.56M | $24.55M | $21.38M | $21.44M | $20.03M | $20.51M | $17.03M | $6.12M | $801.79K | $45.59K | $1.14M | $415.19K | $1.83M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 5 | 7 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 12 | 11 | 10 | 10 | 9 | 8 | 13 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | - | - | 0.94% | 1.01% | - | - | 1.09% | 1.03% | 0.99% | 1.08% | 1.12% | 1.04% | 2.30% | 8.08% | 1.09% | - | - | 12.50% |
Deciphera Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 5 analysts is $46.20M, with a low forecast of $46.20M, and a high forecast of $46.20M. DCPH's average Quarter revenue forecast represents a -4.34% decrease compared to the company's last Quarter revenue of $48.29M (Dec 23).
Deciphera Pharmaceuticals EBITDA Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 5 | 7 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 12 | 11 | 10 | 10 | 9 | 8 | 13 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | $-50.78M | - | - | $-53.26M | $-47.16M | - | - | $-46.89M | $-87.61M | $-78.91M | $-69.61M | $-60.37M | $-61.79M | $-62.74M | $-65.07M | $-69.89M | $-66.76M | $-56.01M | $-21.32M |
| Avg Forecast | $-72.50M | $-62.53M | $-55.60M | $-50.40M | $-54.83M | $-53.33M | $-49.46M | $-61.99M | $-45.93M | $-39.45M | $-36.09M | $-56.36M | $-35.97M | $-93.63M | $-30.56M | $-51.23M | $-86.44M | $-74.02M | $-66.05M | $-60.57M | $-64.74M | $-71.28M | $-75.04M | $-65.98M | $-1.25M | $-51.04M | $-28.70M |
| High Forecast | $-72.50M | $-62.53M | $-55.60M | $-50.40M | $-54.83M | $-53.33M | $-45.19M | $-49.59M | $-42.94M | $-37.59M | $-36.09M | $-45.08M | $-35.97M | $-74.90M | $-30.56M | $-40.99M | $-69.15M | $-59.21M | $-52.84M | $-48.45M | $-51.79M | $-57.02M | $-60.03M | $-52.78M | $-1.14M | $-40.83M | $-22.96M |
| Low Forecast | $-72.50M | $-62.53M | $-55.60M | $-50.40M | $-54.83M | $-53.33M | $-51.95M | $-74.39M | $-47.26M | $-41.44M | $-36.09M | $-67.63M | $-35.97M | $-112.36M | $-30.56M | $-61.48M | $-103.73M | $-88.82M | $-79.26M | $-72.68M | $-77.69M | $-85.53M | $-90.05M | $-79.18M | $-1.32M | $-61.25M | $-34.44M |
| Surprise % | - | - | - | - | - | - | - | - | 1.11% | - | - | 0.95% | 1.31% | - | - | 0.92% | 1.01% | 1.07% | 1.05% | 1.00% | 0.95% | 0.88% | 0.87% | 1.06% | 53.41% | 1.10% | 0.74% |
undefined analysts predict DCPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Deciphera Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Deciphera Pharmaceuticals Net Income Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 5 | 7 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 12 | 11 | 10 | 10 | 9 | 8 | 13 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | $-47.19M | - | - | $-45.96M | $-45.94M | - | - | $-46.11M | $-88.40M | $-79.84M | $-70.43M | $-61.30M | $-62.74M | $-63.70M | $-67.24M | $-72.81M | $-67.22M | $-56.20M | $-21.46M |
| Avg Forecast | $-27.09M | $-36.41M | $-40.78M | $-43.69M | $-44.25M | $-43.43M | $-46.25M | $-63.04M | $-50.70M | $-53.25M | $-54.18M | $-57.31M | $-48.75M | $-94.73M | $-57.49M | $-52.10M | $-87.21M | $-74.89M | $-66.76M | $-61.30M | $-65.47M | $-72.03M | $-75.58M | $-66.40M | $-99.90M | $-49.29M | $-28.88M |
| High Forecast | $-27.09M | $-36.41M | $-40.78M | $-43.69M | $-44.25M | $-43.43M | $-37.84M | $-50.43M | $-43.70M | $-48.89M | $-54.18M | $-45.85M | $-48.75M | $-75.79M | $-57.49M | $-41.68M | $-69.77M | $-59.91M | $-53.41M | $-49.04M | $-52.37M | $-57.62M | $-60.47M | $-53.12M | $-88.66M | $-39.44M | $-23.11M |
| Low Forecast | $-27.09M | $-36.41M | $-40.78M | $-43.69M | $-44.25M | $-43.43M | $-55.50M | $-75.65M | $-56.82M | $-59.37M | $-54.18M | $-68.77M | $-48.75M | $-113.68M | $-57.49M | $-62.52M | $-104.65M | $-89.86M | $-80.11M | $-73.56M | $-78.56M | $-86.44M | $-90.70M | $-79.68M | $-106.97M | $-59.15M | $-34.66M |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | - | - | 0.80% | 0.94% | - | - | 0.88% | 1.01% | 1.07% | 1.06% | 1.00% | 0.96% | 0.88% | 0.89% | 1.10% | 0.67% | 1.14% | 0.74% |
Deciphera Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DCPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Deciphera Pharmaceuticals SG&A Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 5 | 7 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 12 | 11 | 10 | 10 | 9 | 8 | 13 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | $39.15M | - | - | $31.45M | $32.20M | - | - | $28.32M | $37.15M | $35.53M | $32.83M | $30.75M | $30.07M | $30.14M | $29.93M | $23.94M | $23.74M | $17.98M | $13.16M |
| Avg Forecast | $124.47M | $107.36M | $95.46M | $86.53M | $94.13M | $91.56M | $84.91M | $38.08M | $78.86M | $67.73M | $61.97M | $34.61M | $61.76M | $56.80M | $52.47M | $46.14M | $40.18M | $40.29M | $37.64M | $38.56M | $32.02M | $11.51M | $1.51M | $97.83K | $2.15M | $780.39K | $3.43M |
| High Forecast | $124.47M | $107.36M | $95.46M | $86.53M | $94.13M | $91.56M | $89.18M | $45.69M | $81.14M | $71.15M | $61.97M | $41.54M | $61.76M | $56.80M | $52.47M | $48.65M | $42.37M | $42.49M | $39.69M | $40.66M | $33.76M | $12.14M | $1.59M | $117.40K | $2.26M | $822.87K | $3.62M |
| Low Forecast | $124.47M | $107.36M | $95.46M | $86.53M | $94.13M | $91.56M | $77.59M | $30.46M | $73.72M | $64.54M | $61.97M | $27.69M | $61.76M | $56.80M | $52.47M | $42.15M | $36.70M | $36.80M | $34.38M | $35.22M | $29.25M | $10.52M | $1.38M | $78.27K | $1.96M | $712.83K | $3.14M |
| Surprise % | - | - | - | - | - | - | - | - | 0.50% | - | - | 0.91% | 0.52% | - | - | 0.61% | 0.92% | 0.88% | 0.87% | 0.80% | 0.94% | 2.62% | 19.86% | 244.66% | 11.06% | 23.04% | 3.83% |
Deciphera Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $38.08M, based on 5 Wall Street analysts, with a range of $30.46M to $45.69M. The forecast indicates a -2.74% fall compared to DCPH last annual SG&A of $39.15M (Dec 23).
Deciphera Pharmaceuticals EPS Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 5 | 7 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 12 | 11 | 10 | 10 | 9 | 8 | 13 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.56 | $-0.60 | - | - | $-0.79 | $-1.51 | $-1.37 | $-1.21 | $-1.06 | $-1.11 | $-1.13 | $-1.20 | $-1.36 | $-1.31 | $-1.28 | $-0.56 |
| Avg Forecast | $-0.31 | $-0.42 | $-0.47 | $-0.50 | $-0.51 | $-0.50 | $-0.53 | $-0.55 | $-0.58 | $-0.61 | $-0.62 | $-0.59 | $-0.56 | $-0.58 | $-0.66 | $-0.90 | $-1.38 | $-1.24 | $-1.16 | $-1.07 | $-1.16 | $-1.30 | $-1.37 | $-1.25 | $-1.15 | $-1.14 | $-1.11 |
| High Forecast | $-0.31 | $-0.42 | $-0.47 | $-0.50 | $-0.51 | $-0.50 | $-0.43 | $-0.55 | $-0.50 | $-0.56 | $-0.62 | $-0.59 | $-0.56 | $-0.58 | $-0.66 | $-0.80 | $-1.22 | $-1.10 | $-1.03 | $-0.95 | $-1.03 | $-1.15 | $-1.21 | $-1.11 | $-1.02 | $-1.01 | $-0.98 |
| Low Forecast | $-0.31 | $-0.42 | $-0.47 | $-0.50 | $-0.51 | $-0.50 | $-0.64 | $-0.55 | $-0.65 | $-0.68 | $-0.62 | $-0.59 | $-0.56 | $-0.58 | $-0.66 | $-0.96 | $-1.48 | $-1.33 | $-1.24 | $-1.14 | $-1.24 | $-1.39 | $-1.46 | $-1.34 | $-1.23 | $-1.22 | $-1.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.08% | - | - | 0.88% | 1.09% | 1.10% | 1.05% | 0.99% | 0.96% | 0.87% | 0.88% | 1.08% | 1.14% | 1.13% | 0.51% |
According to undefined Wall Street analysts, Deciphera Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DCPH previous annual EPS of $NaN (undefined).
Deciphera Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.85 | $10.00 | 440.54% | - |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| EVO | Evotec SE | $3.54 | $8.00 | 125.99% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| SUPN | Supernus Pharmaceuticals | $31.11 | $38.00 | 22.15% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| AVDL | Avadel Pharmaceuticals | $13.70 | $14.75 | 7.66% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
DCPH Forecast FAQ
Is Deciphera Pharmaceuticals a good buy?
No, according to 10 Wall Street analysts, Deciphera Pharmaceuticals (DCPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of DCPH's total ratings.
What is DCPH's price target?
Deciphera Pharmaceuticals (DCPH) average price target is $26.32 with a range of $25 to $30, implying a 2.85% from its last price of $25.59. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Deciphera Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for DCPH stock, the company can go up by 2.85% (from the last price of $25.59 to the average price target of $26.32), up by 17.23% based on the highest stock price target, and down by -2.31% based on the lowest stock price target.
Can Deciphera Pharmaceuticals stock reach $40?
DCPH's average twelve months analyst stock price target of $26.32 does not support the claim that Deciphera Pharmaceuticals can reach $40 in the near future.
What are Deciphera Pharmaceuticals's analysts' financial forecasts?
Deciphera Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $203.82M (high $206.31M, low $199.55M), average EBITDA is $-220M (high $-203M, low $-234M), average net income is $-197M (high $-176M, low $-219M), average SG&A $308.68M (high $320.57M, low $293.75M), and average EPS is $-2.087 (high $-1.991, low $-2.193). DCPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $241.03M (high $241.03M, low $241.03M), average EBITDA is $-241M (high $-241M, low $-241M), average net income is $-148M (high $-148M, low $-148M), average SG&A $413.82M (high $413.82M, low $413.82M), and average EPS is $-1.693 (high $-1.693, low $-1.693).
Did the DCPH's actual financial results beat the analysts' financial forecasts?
Based on Deciphera Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $163.36M, beating the average analysts forecast of $157.16M by 3.94%. Apple's EBITDA was $-211M, beating the average prediction of $-178M by 18.63%. The company's net income was $-195M, missing the average estimation of $-215M by -9.52%. Apple's SG&A was $136.46M, missing the average forecast of $243.17M by -43.88%. Lastly, the company's EPS was $0, missing the average prediction of $-2.403 by -100.00%. In terms of the last quarterly report (Dec 2023), Deciphera Pharmaceuticals's revenue was $48.29M, beating the average analysts' forecast of $45.93M by 5.14%. The company's EBITDA was $-50.782M, beating the average prediction of $-45.934M by 10.56%. Deciphera Pharmaceuticals's net income was $-47.19M, missing the average estimation of $-50.697M by -6.92%. The company's SG&A was $39.15M, missing the average forecast of $78.86M by -50.36%. Lastly, the company's EPS was $0, missing the average prediction of $-0.58 by -100.00%